Shares of Bliss GVS Pharma declined in early trade on March 20 after the company received three observations from the United States Food and Drug Administration (USFDA).
The USFDA had conducted a pre-approval inspection (PAI) and good manufacturing practice (GMP) inspection at Bliss GVS Pharma's manufacturing unit at Palghar, Maharashtra, during March 13 to 17, according to a press release.
After the inspection, the USFDA issued Form 483 with three minor observations, which are procedural in nature and none of the observations relate to data integrity, the company said.
Catch all the market action on our live blog
The company shall prepare detailed response to the observations, which will be submitted to the USFDA within the stipulated timelines, it added.
The company remains committed to maintain the highest standards of compliance and will work closely with the agency to comprehensively address all the observations, the company said.
At 9:22am, Bliss GVS Pharma was quoting at Rs 75.08, down Rs 0.11, or 0.15 percent, on the BSE.
Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!
Find the best of Al News in one place, specially curated for you every weekend.
Stay on top of the latest tech trends and biggest startup news.
